Is Pirfenidone on the market?

Pirfenidone (Pirfenidone has been approved by the US Food and Drug Administration (FDA) for sale under the trade name Esbriet and has also been approved by the European Medicines Agency (EMA). In 2018, pirfenidone was approved by the National Medical Products Administration and was launched in China under the trade name of Asri, and it was included in the scope of Class B medical insurance.

Pirfenidone is a drug used to treat idiopathic pulmonary fibrosis in adults(IPF). IPF is a long-term disease in which fibrous scar tissue continuously builds up in the lungs, causing persistent coughing, frequent lung infections, and severe shortness of breath. "Idiopathic" means the cause of the disease is unknown. Pirfenidone, available in capsule and tablet form, contains the active ingredient Pirfenidone, which has been shown to slow the progression of IPF without serious risks to patients. However, pirfenidone should not be used in patients who are already taking fluvoxamine (a drug used to treat depression and obsessive-compulsive disorder), who have previously developed angioedema (rapid swelling of areas such as the face and throat that can cause difficulty breathing) while using pirfenidone, or patients who have severe liver or kidney problems.

Domestic medical insurance reimbursement for pirfenidone is limited to patients with idiopathic pulmonary fibrosis. The specifications produced by domestic pharmaceutical factoriesThe price of 100mg*54 tablets per box is around RMB 500. There are also generic pirfenidone drugs produced in other countries overseas. For example, the price of a box of 200mg*30 tablets produced by an Indian pharmaceutical factory is around RMB 100 (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.